Some of the names on the move ahead of the open.» Read More
We all make mistakes. Gosh knows I've made more than a few. And a part of me hesitates to call attention to this one. I mean, you know what they say about paybacks and karma. But this one is too good a doozy to let pass.
Everyone loves a winner. Following are the best performing stocks for 2008 for the Dow, Nasdaq and the S&P. But will they perform as well this year?
Will Santa squeak in a rally before the ball drops? Early moves suggest it could happen: Stocks continued to rise Tuesday, adding to the more than 2-percent gain logged on Wednesday.
Now that 2008 is just about over, here's a look at the top yielding stocks in the Dow that would make up your portfolio if you followed the popular Dogs of the Dow investment strategy.
Another light volume, low volatility day, closing near the highs. Good news, considering that the consumer confidence and home price news was dismal. Goldman Sachs had a particularly good day, up almost 6 percent, though on light volume. But GMAC was the big story of the day...
Stocks rallied to the finish line as investors shrugged off a drop in consumer confidence and cheered the bailout of General Motors' finance arm.
Bill Spiropoulos of CoreStates Capital Advisors thinks investors should be buying stocks right now. Actually, he doesn't just think. He insists.
With some markets already closed for the year and others just about wrapped up, here is a summary of how the major global indices fared in 2008.
The New York Times recapps some of the high and low points in advertising in 2009.
Options traders Tuesday are betting on more upside in medical technology company Stryker. Following heavy volume yesterday, SYK continues to see activity at the January 40 calls...
Riverfront Investment Group's Rod Smyth characterizes the current efforts of the Federal Reserve and the Treasury as "one huge bridge...trying to take us from this recession that we're in, into the next expansion." Mike Holland of Holland & Co. agrees — and says some investment opportunities are also being built.
Drug pricing pressure under a Democratic administration be darned. $75,000. That's not a salary figure. That's the price one biotech analyst says Vertex Pharmaceuticals and its partner Johnson & Johnson might be able to charge--possibly even more--for their Hepatitis C drug.
The much discussed "investor fear gauge", or the VIX closed below $50 for the first time since it closed at $47.43 on November 4. Are things beginning to stabilize?
We finished the day down, but these two guys were responsible for much of the trading session’s strength, Cramer says.
BlackRock's Bob Doll thinks it's time to put some risk back into your stock portfolio.
GM’s failure points are extensive, but nothing is more glaring than its resolute myopia. Throughout its history, GM anointed itself the final arbiter of customer needs and wants.
Cramer makes the call on viewers' favorite stocks.
Thursday was a busy day in options on Charles Schwab, according to Rebecca Darst of NYSE Euronext. There was also wide-ranging options action among companies that make medical devices.
Fortune Magazine is looking ahead to 2009 with a list of 10 promising stocks. Senior editor Leigh Gallagher says, "When markets return, they return in force. Usually, after a bear market, in the first nine months, the market goes up by an average of 32 percent, so if you wait, you risk missing big momentum."
The week ended with a stunningly bad November jobs report, indicating that the economy is getting much worse much faster than expected, and suggesting that the recession will be especially deep and prolonged. It was a grim end to a volatile week, beginning with a huge loss on Monday, but CNBC guests continued to encourage investors to buy stocks, saying now is the time to position oneself for the recovery and take advantage of valuations.